J Sludden
Overview
Explore the profile of J Sludden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
513
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Plummer R, Wilson R, Calvert H, Boddy A, Griffin M, Sludden J, et al.
Br J Cancer
. 2011 Feb;
104(4):593-8.
PMID: 21285987
Background: On the basis of preclinical studies of NC-6004, a cisplatin-incorporated micellar formulation, we hypothesised that NC-6004 could show lower toxicity than cisplatin and show greater anti-tumour activity in phase...
2.
Bray J, Sludden J, Griffin M, Cole M, Verrill M, Jamieson D, et al.
Br J Cancer
. 2010 Feb;
102(6):1003-9.
PMID: 20179710
Background: Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer. Doxorubicin is a substrate for ABCB1 and SLC22A16 transporters. Cyclophosphamide is a prodrug that requires oxidation...
3.
Boddy A, Griffin M, Sludden J, Thomas H, Fishwick K, Wright J, et al.
Cancer Chemother Pharmacol
. 2001 Aug;
48(1):15-21.
PMID: 11488519
Purpose: To determine the effect on systemic pharmacology and clinical toxicity of dose and mode of administration of paclitaxel combined with carboplatin in the treatment of ovarian cancer. Patients And...
4.
Plumb J, Strathdee G, Sludden J, Kaye S, Brown R
Cancer Res
. 2000 Nov;
60(21):6039-44.
PMID: 11085525
Loss of DNA mismatch repair because of hypermethylation of the hMLH1 gene promoter occurs at a high frequency in a number of human tumors. A role for loss of mismatch...
5.
Morsman J, Sludden J, Ameyaw M, Githanga J, Indalo A, Ofori-Adjei D, et al.
Br J Clin Pharmacol
. 2000 Sep;
50(3):269-72.
PMID: 10971312
Aims: Dihydropyrimidine dehydrogenase (DPD) reduces endogenous pyrimidines and therapeutic analogues such as the anticancer agent 5-fluorouracil (5FU). Among Caucasian populations DPD activity is highly variable and subject to polymorphic regulation....
6.
Sludden J, Uchegbu I, Schatzlein A
J Pharm Pharmacol
. 2000 May;
52(4):377-82.
PMID: 10813546
Polymeric vesicles have recently been developed from an amphiphilic chitosan derivative--palmitoyl glycol chitosan. Their potential as a drug delivery system was evaluated using the anti-cancer compound bleomycin as a model...
7.
Twelves C, Gardner C, Flavin A, Sludden J, Dennis I, de Bono J, et al.
Br J Cancer
. 1999 Sep;
80(11):1786-91.
PMID: 10468297
DACA, also known as XR5000, is an acridine derivative active against both topoisomerase I and II. In this phase I study, DACA was given as a 3-h intravenous infusion on...
8.
Stevenson J, DEMARIA D, Sludden J, Kaye S, Paz-Ares L, Grochow L, et al.
Ann Oncol
. 1999 Jun;
10(3):339-44.
PMID: 10355580
Background: Preclinical results support a prolonged schedule of administration for topoisomerase I inhibitors, and we have previously demonstrated the safety and activity of the novel water-soluble topoisomerase I inhibitor GG211...
9.
Pritchard S, Powrie R, Sludden J, Collier D, Li T, McLeod H
Pharmacogenetics
. 1999 Apr;
9(1):37-42.
PMID: 10208641
Thiopurine methyltransferase metabolizes 6-mercaptopurine, thioguanine and azathioprine, thereby regulating cytotoxicity and clinical response to these thiopurine drugs. In healthy Caucasian populations, 89-94% of individuals have high thiopurine methyltransferase activity, 6-11%...
10.
McLeod H, Sludden J, Hardy S, Lock R, Hawksworth G, Cassidy J
Eur J Cancer
. 1999 Jan;
34(10):1623-7.
PMID: 9893640
5-Fluorouracil (5-FU) is a commonly used anticancer agent for the treatment of gastrointestinal, head and neck, and breast tumours. This study determined the influence of 5-FU on dihydropyrimidine dehydrogenase (DPD)...